Fergus Icilma V, Connell Kenneth L, Ferdinand Keith C
Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA,
Curr Cardiol Rep. 2015 Jun;17(6):38. doi: 10.1007/s11886-015-0592-x.
Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis.
心脏代谢风险描述了一系列风险因素，这些因素可能具有潜在的病理生理学机制，会导致动脉粥样硬化加速以及心肌梗死和中风等终末期心血管事件。β受体阻滞剂分为血管扩张剂和非血管扩张剂，用于治疗高血压和其他心血管疾病。血管扩张剂已被证明在控制血压和其他心脏代谢成分方面具有特别的益处，同时对代谢参数的干扰有限。奈必洛尔是一种第三代β受体阻滞剂（BB），其作用机制是增加一氧化氮（NO）的生物利用度。在缺乏NO的人群（如黑人）中，这一特性在调节血压控制和葡萄糖稳态方面可能尤为重要。
